The commercialization arm of a leading university wished to identify its most promising therapeutic programs within its purview in order to allocate internal translational funding to progress into the clinic. Once a subset of research groups had been selected by the commercialization team, Alacrita was commissioned to create commercial development plans for each program which would be presented to the funding board. One of the programs selected was a Treg cell therapy in preclinical development for the treatment of drug-refractory immune conditions of the liver. The product had potential not only to stop disease progression but was also proposed to provide regenerative effects.
Alacrita met with the research team to discuss the project in more detail, before reviewing all available material and creating the commercial development plan. This plan outlined the potential value in the program and the technical proof of concept milestones that the group had to reach in order to progress their product into first-in-human studies.
Specifically, the document analyzed and outlined the following:
- Background on the technology/invention
- Current stage of development
- Existing proof of concept data
- Development plans
- Competence of the project team
- Intellectual property
- Unmet medical needs addressed by the program
- Market opportunity
- Competitor landscape
- Key risks in the project and steps to mitigate them.
Our report was discussed with the commercialization and research team before a final version was sent to the internal funding committee for review.Back